《世界卫生组织结核病整合指南模块1:结核病预防性治疗》解读  

Interpretation of WHO consolidated guidelines on tuberculosis:Module 1:prevention:tuberculosis preventive treatment

作　　者：郭同磊 辛赫男 高磊[1] Guo Tonglei;Xin Henan;Gao Lei(Institute of Pathogen Biology,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100730,China)

机构地区：[1]中国医学科学院/北京协和医学院病原生物学研究所,北京100730

出　　处：《中国防痨杂志》2023年第8期723-727,共5页Chinese Journal of Antituberculosis

基　　金：中国医学科学院医学与健康科技创新工程项目(2021-I2M-1-037)。

摘　　要：2020年2月25日,世界卫生组织(World Health Organization,WHO)发布WHO consolidated guidelines on tuberculosis:module 1:prevention:tuberculosis preventive treatment(简称《2020版指南》),并发布实施手册,其中包含《2020版指南》实施的具体细节,为指南意见的实施提供指导。《2020版指南》整合了自2018年WHO发布Latent tuberculosis infection:updated and consolidated guidelines for programmatic management以来的最新研究证据,更新了部分推荐意见。笔者现对《2020版指南》进行介绍,对其形成的重点推荐意见加以解读,希望为我国结核病预防性治疗工作提供参考与借鉴。World Health Organization(WHO)published the WHO consolidated guidelines on tuberculosis:Module 1:prevention:tuberculosis preventive treatment(2020 version guideline)on February 25,2020,and guided the implementation of the 2020 version guideline through the implementation manual which contains the details of the implementation of guidance recommendations.The 2020 version guideline integrates the latest research since the WHO released Latent tuberculosis infection:updated and consolidated guidelines for programmatic management in 2018,and updates some recommendations.The author introduces the 2020 version guideline and interprets its key recommendations,hoping to provide a reference for the implementation of tuberculosis preventive treatment in China.

关 键 词：分枝杆菌 结核 感染 预防和防护用药 总结性报告(主题) 

分 类 号：R521[医药卫生—内科学] R825.2[医药卫生—临床医学]